Last reviewed · How we verify
Physicians Choice systemic chemotherapy
At a glance
| Generic name | Physicians Choice systemic chemotherapy |
|---|---|
| Also known as | Olaparib, Paclitaxel, Nab-paclitaxel, Eribulin, Carboplatin |
| Sponsor | Colette Shen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (PHASE1, PHASE2)
- Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer (PHASE3)
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis (PHASE3)
- Functional Precision Oncology for Metastatic Breast Cancer (NA)
- Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery (PHASE3)
- A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physicians Choice systemic chemotherapy CI brief — competitive landscape report
- Physicians Choice systemic chemotherapy updates RSS · CI watch RSS
- Colette Shen portfolio CI